The Latest Cardiac and Vascular News
COLORADO SPRINGS, Colo., July 18, 2024 /PRNewswire/ — Neurointerventional surgeons from across the globe will gather at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting from July 22 through July 25 in Colorado Springs, Colorado, to present novel research and…
Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values
WASHINGTON, July 18, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) recently announced the selection of new officers and board members for the society with terms starting at the conclusion of the HFSA Annual Scientific Meeting 2024 (ASM), which will take place September…
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024.
— Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 — — Approval marks eighth national reimbursement of VAZKEPA® in Europe —
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 […]
July 17, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom™ 6F Insert Catheters, the company’s latest innovation in elevating stroke care and the first insert catheters developed specifically for ischemic stroke procedures. The company […]
MORTSEL, Belgium, July 17, 2024 /PRNewswire/ — At the Annual Meeting of AHRA (the Association for Medical Imaging Management), Agfa Radiology Solutions will demonstrate how its solutions help customers address staffing shortages and tight budgets.
Continue Reading
Agfa’s comprehensive portfolio supports “The Next Generation” in medical imaging by using intelligent and innovative technologies to ensure every X-ray image counts. With accurate and high-quality diagnostic information from the first image taken, retakes are reduced: speeding up workflows and enhancing the experience of radiologist, radiographer and patient.
Agfa Radiology Solutions uses intelligent and innovative technologies to ensure every X-ray image in healthcare counts.
Post this
“We understand the challenges our customers are facing in terms of staffing shortages and decreased budgets. Our productivity features and ‘one image is all it takes’ approach empower each X-ray expert to work more efficiently. Additionally, the DR 100 Essential and VALORY™ are designed to be budget-friendly, but still deliver all the essential functions healthcare facilities need – including our renowned MUSICA® image processing software. They demonstrate our commitment to offering solutions that ensure healthcare facilities never need to compromise on image quality, regardless of their staff and budget constraints,” says Bruce Romaglia, Vice President – North America at Agfa Radiology Solutions.
At Agfa’s booth, visitors can discover solutions and special packages that help bring those advantages to every healthcare organization, whatever their budgets.Intelligent technologies for image processing and workflow assistance:
MUSICA®, which comes standard with all Agfa DR and CR systems, automatically analyses the characteristics of raw images and optimizes the processing parameters, independent of body part or dose deviation. Its high image quality and low-dose features have made MUSICA® the “gold standard” in image processing for radiology departments around the world.
The SmartXR® portfolio adds X-ray intelligence to Agfa’s DR solutions, to provide image acquisition support and lighten the radiographer’s workload. Predictive workflow assistance for dose, alignment, patient positioning, image rotation and more help improve operational performance in image acquisition.
About AgfaAgfa develops, produces and distributes an extensive range of imaging systems and workflow solutions for the printing industry, the healthcare sector, as well as for specific hi-tech industries such as printed electronics & renewable energy solutions.The headquarters are located in Belgium. The largest production and research centers are located in Belgium, the United States, Canada, Germany, France, the United Kingdom, Austria, China and Brazil. Agfa is commercially active worldwide through wholly owned sales organizations in more than 40 countries.For more information on Agfa please visit www.agfa.comFollow us at TwitterAgfa, the Agfa rhombus, MUSICA and SmartXR are trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. All rights reserved.All information contained herein is intended for guidance purposes only, and characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. Agfa diligently strives to provide as accurate information as possible, but shall not be responsible for any typographical error.Only the English version of this press release is legally valid. The versions in other languages only represent a translation of the original English version.SOURCE AGFA US Corp.
Dr. Mettler comes to Le Bonheur from Johns Hopkins Children’s Center
MEMPHIS, Tenn., July 17, 2024 /PRNewswire/ — Le Bonheur Children’s Hospital has named Bret A. Mettler, MD, its new Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute at Le Bonheur and the University of Tennessee Health Science Center. Dr. Mettler will also hold The Susan and Alan Graf Endowed Chair in Pediatric Heart Surgery at Le Bonheur.
He comes to Le Bonheur and UT Health Science Center from Johns Hopkins Children’s Center, where he serves as Director of Pediatric Cardiac Surgery and Co-Director of the Blalock-Taussig-Thomas Pediatric and Congenital Heart Center.
Before his time at Johns Hopkins, Dr. Mettler served as the Director of Cardiac Transplantation and Mechanical Circulatory Support at Vanderbilt University Medical Center in Nashville.
“I am excited for Dr. Mettler to join our talented and dedicated team at Le Bonheur and UT Health Science Center,” said Le Bonheur President Trey Eubanks, MD, FACS. “Bret brings a wealth of knowledge and experience which will allow us to continue our Heart Institute’s mission of providing excellent care for children with complex heart conditions.”
Dr. Mettler specializes in the surgical repair of complex congenital heart disease, heart transplantation and mechanical circulatory support. His research interests include insights into complex congenital heart defects and the development of an artificial pulmonary valve using stem cells.
“Le Bonheur is committed to excellence and providing outstanding care for patients,” said Dr. Mettler. “The Heart Institute has a world-class faculty built by Drs. (Chris) Knott-Craig and (Jeffrey A.) Towbin, and I am pleased to be part of building on that foundation. Le Bonheur really shines for its care for children in an environment built just for them. I am excited about our continued vision for growth and service to the community.”
Le Bonheur Children’s Announces Dr. Brett Mettler, page two of two
Dr. Mettler assumes the chief of Pediatric Cardiac Surgery and executive co-director of the Heart Institute roles from Christopher Knott-Craig, MD, who last year announced he plans to step down as chief and executive co-director of the Heart Institute. Dr. Knott-Craig, along with Dr. Jeffrey A. Towbin, the executive co-director of the Heart Institute and chief of Pediatric Heart Failure and medical director of Cardiomyopathy, Heart Failure and Heart Transplant Services, have been responsible for leading Le Bonheur’s Heart Institute to become a Top 10 program in U.S. News & World Report. They have built the reputation of Le Bonheur’s Heart Institute as an elite surgical and medical program and developed the new 31-bed Cardiovascular Intensive Care Unit. Le Bonheur will honor Knott-Craig and his tenure later this summer.
“I want to thank the medical, surgical and nursing members of the Heart Institute for their very substantial role in helping to recruit Dr. Mettler and for their long-term commitment to excellence and the special care given to their patients,” said Dr. Towbin, who also serves as chief of Cardiology at Le Bonheur and St. Jude Children’s Research Hospital and tenured professor, Department of Pediatrics, Pediatric Cardiology at UT Health Science Center. “I am excited for Le Bonheur’s future and for the innovation that Dr. Mettler brings to Memphis. He is a wonderful addition to our outstanding team.”
Dr. Mettler is a native of South Dakota. He, along with his wife Kelly and their two daughters, will move to Memphis later this year.
About Le Bonheur Children’s Le Bonheur Children’s, based in Memphis, Tenn., provides expert care for children in more than 45 pediatric subspecialties, encompassing robust community programs, a pediatric research institute and regional outpatient centers in Jackson, Tenn., Tupelo, Miss., and Jonesboro, Ark. Le Bonheur also features a 255-bed hospital in Memphis and a 21-bed satellite hospital within Jackson-Madison County General Hospital in Jackson, Tenn. As the primary pediatric teaching affiliate for the University of Tennessee Health Science Center, Le Bonheur trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur has been named a U.S. News & World Report Best Children’s Hospital for 13 consecutive years and is a Magnet-designated facility, the ultimate credential for high-quality patient care and nursing excellence.
For more information, please call (901) 287-6030 or visit lebonheur.org. Connect with us at facebook.com/lebonheurchildrens, x.com/lebonheurchild on Instagram at lebonheurchildrens.
About University of Tennessee Health Science CenterThe mission of the University of Tennessee Health Science Center is transforming lives through collaborative and inclusive education, research, scholarship, clinical care, and public service. With six colleges – Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy – at its main campus in Memphis, in addition to educational and clinical campuses at major hospitals in Memphis, Knoxville, Chattanooga, and Nashville, and sites across the state, UT Health Science Center strives to fulfill its vision: Healthy Tennesseans. Thriving Communities. For more information, visit www.uthsc.edu. You can find the University of Tennessee Health Science Center on Facebook, Instagram, LinkedIn, X, and YouTube.
CONTACT: David Henson(423) 304-9400 [email protected]
Ariss Arena (901) 283-5584 [email protected]
SOURCE Le Bonheur Children’s Hospital
New Codes Establish Path to Reimbursement for First-of-its-Kind Cardiac Technology
MOUNTAIN VIEW, Calif., July 17, 2024 /PRNewswire/ — AliveCor, the global leader in AI-powered cardiology, today announced that the American Medical Association (AMA) has granted new Category III Current Procedural Terminology (CPT) codes that are applicable to the company’s Kardia™ 12L ECG System, which received FDA clearance in June 2024. In accordance with the AMA semi-annual early release schedule, the new codes will be effective January 1st, 2025 and published in the 2025 CPT Code book.
CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. Category III CPT codes allow data collection for new or emerging healthcare approaches and establish a foundation that facilitates reimbursement pathways for healthcare providers.
The following Category III codes for Kardia 12L were accepted by the CPT Editorial Panel meeting for the 2025 CPT production cycle:
0903T Electrocardiogram, Algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report
0904T ECG ALG 12 Algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only
0905T Electrocardiogram, Algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only
“Cardiovascular disease continues to be the leading cause of death in the US, and this recognition from the AMA brings new momentum towards improving access to life-saving cardiac care, including our latest technology,” said Sanjay Voleti, CBO of AliveCor. “Our AI-powered, portable Kardia 12L is AliveCor’s first device developed exclusively for use by healthcare providers, paving the way to bring this clinically-validated ECG technology to patients anytime and anywhere.”
About Kardia 12L ECG and KAI 12L AI Technology
Kardia 12L ECG System combines the power of KAI 12L’s AI technology and the pocket-sized Kardia 12L, to enable faster, easier detection of life-threatening cardiac conditions. KAI 12L is the world’s first AI to detect 35 cardiac determinations, including heart attacks, using a reduced leadset.
Kardia 12L ECG System is battery-operated, weighs just 0.3 pounds – making it significantly smaller, more portable and easier to use than conventional 12-lead ECGs. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler and faster to use than standard 12-lead ECG machines. These features put 12-lead ECG data within reach of more healthcare providers than ever before in a variety of healthcare facilities and acute settings, including primary and urgent care offices, employer clinics, and other under-resourced or rural venues.
For healthcare providers interested in purchasing a Kardia 12L, please visit alivecor.com/products/kardia12L.
About AliveCor
AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With over 250 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.
SOURCE AliveCor, Inc.
